Insider trade

Officer sold ~$197K of UTHR shares in the open market

Traded Apr 2, 2026 · Filed Apr 3, 2026

Why it stands out

United Therapeutics's & GENERAL COUNSEL sold $197K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$197,152

Shares × reported transaction price

Timing vs results

36 days after results of Feb 25, 2026, 34 days before results of May 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+3.2%	+4.1%	−0.9%
30 days	+6.6%	+11.4%	−4.7%
90 days	−2.2%	+14.0%	−16.2%
180 days	−4.2%	+17.6%	−21.7%

Past results only. Not a forecast.

This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
This transaction was executed in multiple trades at prices ranging from $560.885 to $561.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 5mo ago

Traded Apr 30 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 5mo ago

Scheduled in advanceFiled 5mo ago